The Global Market for Sleep-Wake Disorders Currently Estimated at US$4.3 billion is Forecast to Increase 158% to US$11 billion by 2012.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c29345) has announced the addition of the Spectra Intelligence report "The Global Market for Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in A High-Value CNS Therapy Area" to their offering.

The market for sleep-wake disorders is expanding based on new indications and novel drugs which offer efficacious sleep solutions and wake-promoting effects while limiting adverse side effects that are associated with conventional drugs. In a global market estimated at US$4.3 billion and forecast to increase 158% to US$11 billion by 2012, drugs for sleep-wake disorders such as insomnia, excessive daytime sleepiness, shift-work sleep disorder, sleep apnoea, and restless legs syndrome are predicted to transform the market to a high-value CNS therapy area within a decade. Furthermore, new therapies in the pipeline that provide complete sleep solutions to patients with impaired sleep-wake rhythms or drugs that improve wakefulness in occupational settings will offer new market opportunities and treatment options.

Trailblazer Cephalon has been integral in expanding the wake-promotion sector with Provigil and has stimulated the market to develop more drugs for conditions such as sleep apnoea, occupational shift-work disorders, and delayed-phase circadian rhythm disorders. Despite an optimistic outlook, immediate challenges in the market include short-term saturation in the insomnia therapy area as three new products were recently approved, namely Ambien CR, Lunesta, and Rozerem, with up to four further drugs expected to be approved and launched over the next 18 months including Indiplon, Gaboxadol, Doxepin, and Posidorm. In view of expanded product choice companies will need to adopt aggressive marketing approaches and utilize key therapeutic differentiators to claim market share for their products. However, the majority of sleep-wake disorders are underdiagnosed or misdiagnosed which indicates a significant market opportunity for manufacturers to redefine marketing strategies to optimize revenues for their products. This report comments on strategic and commercial issues that may affect current product positioning and discusses key compounds that have the potential to become high-value products over the next decade. The report also provides insights into forthcoming market dynamics and product sales to 2012 to enable the reader to make assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Report Highlights and Key Findings:

--The current market for sleep-wake disorders is valued at US$4.3 billion, which is forecast to increase 158% CAGR to US$11 billion by 2012

--Critical analysis of insomnia, excessive daytime sleepiness, narcolepsy, sleep apnoea, shift-work sleep disorder, and restless legs syndrome

--Review of epidemiological, aetiological, and demographic data for sleep-wake disorders

--Analysis of over 10 key marketed products and inclusion of 30 R&D candidates identified in preclinical to clinical stages of development for sleep-wake disorders

--Sales estimates (US$) to 2012 for major therapy areas

--Strategic insights for life-cycle optimization and product development

--Critical evaluation of leading sleep-wake disorder pharmacotherapies

--Trend analysis of industry events and activities over past 2 years

--Detailed R&D themes and clusters by therapy area

--Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)

--High revenue-yielding prospects identified with projected sales estimations

--R&D pipeline positioning for novel candidates

--Market insights for product development and drug promotion

What Can I Learn From This Report?

--Which sleep-wake pharmacotherapies are the current and potential future market leaders?

--Insights into the demographics and aetiology of sleep-wake disorders

--What impact new drug approvals will have on the sleep-wake disorder market?

--Which premarket drugs are identified as high-value products?

--Which companies are developing drugs for sleep-wake disorders?

--Sales predictions to 2012 for discrete therapy areas

--How will newcomers affect the product positioning of market leaders such as Ambien?

--Which sectors could be niche market opportunities?

--What the future outlook holds for sleep disorder pharmacotherapies

--How companies are widening the global sleep-wake market through supplementary indications

--Which molecules and compounds are main R&D clusters for sleep-wake disorders?

--Which of the pipeline candidates are identified as top prospects over the next decade and to 2020?

Companies Mentioned:

Alliance Pharma - Arena Pharmaceuticals - Bentley Pharmaceuticals - Barr Laboratories - Biovail- Boehringer Ingelheim - Btg - Caraco Pharmaceuticals - Cephalon - Cortex Pharmaceuticals - Cypress Bioscience - Elan - Fabre-Kramer Pharmaceuticals - Glaxosmithkline - Jazz Pharmaceuticals - King Pharmaceuticals - Kyowa Pharmaceutical - Lilly - Lundbeck - Merck & Co - Neurocrine Biosciences - Neurogen - Organon - Orphan Medical - Pfizer - Phase 2 Discovery - Pherin Pharmaceuticals - Questcor Pharmaceuticals - Sanofi-Aventis - Sepracor - Somaxon Pharmaceuticals - Schwarz Pharma - Takeda Pharmaceuticals - Vanda Pharmaceuticals - Wyeth - Xenoport

For more information visit http://www.researchandmarkets.com/reports/c29345